Table 2.
Pathologic characteristics of index DCIS*
| Characteristics | No. (%) |
|---|---|
| Tumor size (# of LPF) | |
| 1–5 | 65 (35.7) |
| 6–9 | 29 (15.9) |
| 10–19 | 41 (22.5) |
| ≥20 | 47 (25.8) |
| Margin (mm from tumor) | |
| Positive | 25 (13.7) |
| <1 | 64 (35.2) |
| 1–3 | 20 (11) |
| >3 | 49 (26.9) |
| Unknown | 24 (13.2) |
| Nuclear grade | |
| High | 67 (36.8) |
| Intermediate | 103 (56.6) |
| Low | 12 (6.6) |
| Estrogen receptor† | |
| Positive | 134 (73.6) |
| Negative | 25 (13.7) |
| Unknown | 23 (12.6) |
| Progesterone receptor† | |
| Positive | 113 (62.1) |
| Negative | 36 (19.8) |
| Unknown | 33 (18.1) |
| Histology Subtype | |
| Comedo | 114 (62.6) |
| Non-comedo | 68 (37.4) |
| HER2† | |
| 0–1+ | 92 (50.5) |
| 2+ | 32 (17.6) |
| 3+ | 26 (14.3) |
| Unknown | 32 (17.6) |
| LCIS† | |
| Present | 17 (9.3) |
| Absent | 165 (90.7) |
*
Abbreviations: DCIS = ductal carcinoma in situ; # LPF = number of involved low power fields; HER2 = human epidermal growth factor receptor 2; LCIS = lobular carcinoma in situ
†
Immuno-histochemical analysis obtained via central pathology review